2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.
Stacy Loeb, MD, assistant professor of urology and population health at NYU Langone School of Medicine, discusses the results and impact of active surveillance on patients with prostate cancer.
Of the patients who could be considered candidates for active surveillance, one-fifth of those patients had higher Decipher scores, indicating a greater risk of aggressive disease, states Loeb. However, there were patients with intermediate-risk disease who had low Decipher scores.
Now that there are more testing options, patients do not have to rely on one biopsy test, explains Loeb. There are imaging and genomic tests that can give a patient more data and help determine if they are candidates for active surveillance.
Related Content: